KR20050116168A - 위장 손상의 예방 및 치료를 위한감마-아미노부티르산(ｇａｂａ) 동족체 - Google Patents
위장 손상의 예방 및 치료를 위한감마-아미노부티르산(ｇａｂａ) 동족체 Download PDFInfo
- Publication number
- KR20050116168A KR20050116168A KR1020057022543A KR20057022543A KR20050116168A KR 20050116168 A KR20050116168 A KR 20050116168A KR 1020057022543 A KR1020057022543 A KR 1020057022543A KR 20057022543 A KR20057022543 A KR 20057022543A KR 20050116168 A KR20050116168 A KR 20050116168A
- Authority
- KR
- South Korea
- Prior art keywords
- gabapentin
- pain
- gaba
- ethanol
- gastrointestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000006378 damage Effects 0.000 title abstract description 27
- 230000002496 gastric effect Effects 0.000 title abstract description 25
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims abstract description 164
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 133
- 229960002870 gabapentin Drugs 0.000 claims abstract description 81
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims abstract description 39
- 238000011282 treatment Methods 0.000 claims abstract description 25
- 229960001233 pregabalin Drugs 0.000 claims abstract description 18
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract description 85
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract description 39
- 206010048010 Withdrawal syndrome Diseases 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 54
- 241001465754 Metazoa Species 0.000 description 43
- 230000000694 effects Effects 0.000 description 42
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 38
- 241000700159 Rattus Species 0.000 description 36
- 208000002193 Pain Diseases 0.000 description 33
- 230000036407 pain Effects 0.000 description 31
- 210000001072 colon Anatomy 0.000 description 29
- 229960000905 indomethacin Drugs 0.000 description 27
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 20
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 18
- 208000018522 Gastrointestinal disease Diseases 0.000 description 18
- 239000011780 sodium chloride Substances 0.000 description 18
- 239000002158 endotoxin Substances 0.000 description 17
- 235000012054 meals Nutrition 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 16
- 229920006008 lipopolysaccharide Polymers 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 206010010904 Convulsion Diseases 0.000 description 14
- 230000006399 behavior Effects 0.000 description 14
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 239000003981 vehicle Substances 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 208000009935 visceral pain Diseases 0.000 description 11
- 230000003187 abdominal effect Effects 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 208000002551 irritable bowel syndrome Diseases 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 206010003694 Atrophy Diseases 0.000 description 8
- 230000037444 atrophy Effects 0.000 description 8
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 8
- -1 phenopropene Chemical compound 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000000112 colonic effect Effects 0.000 description 6
- 230000010339 dilation Effects 0.000 description 6
- 201000006549 dyspepsia Diseases 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 240000008042 Zea mays Species 0.000 description 5
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 5
- 230000036461 convulsion Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 235000009973 maize Nutrition 0.000 description 5
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 5
- 206010003591 Ataxia Diseases 0.000 description 4
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 4
- 208000007101 Muscle Cramp Diseases 0.000 description 4
- 206010044565 Tremor Diseases 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 229960005181 morphine Drugs 0.000 description 4
- 230000037023 motor activity Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000007848 Alcoholism Diseases 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 206010061172 Gastrointestinal injury Diseases 0.000 description 3
- 208000004454 Hyperalgesia Diseases 0.000 description 3
- 208000035154 Hyperesthesia Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000008469 Peptic Ulcer Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 201000007930 alcohol dependence Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 210000000436 anus Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 229960002009 naproxen Drugs 0.000 description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
- 229960003940 naproxen sodium Drugs 0.000 description 3
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000011435 rock Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 208000037911 visceral disease Diseases 0.000 description 3
- 230000009278 visceral effect Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- CVKMFSAVYPAZTQ-UHFFFAOYSA-N 2-methylhexanoic acid Chemical compound CCCCC(C)C(O)=O CVKMFSAVYPAZTQ-UHFFFAOYSA-N 0.000 description 2
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 208000002033 Myoclonus Diseases 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 206010036772 Proctalgia Diseases 0.000 description 2
- 101100008035 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CUE3 gene Proteins 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 2
- 229960005054 acepromazine Drugs 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 229960000616 diflunisal Drugs 0.000 description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000003194 forelimb Anatomy 0.000 description 2
- 229940015508 gabapentin 100 mg Drugs 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 208000009326 ileitis Diseases 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960003464 mefenamic acid Drugs 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960000894 sulindac Drugs 0.000 description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IUVMAUQEZFTTFB-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid Chemical compound CC1CC(CN)(CC(O)=O)CC1C IUVMAUQEZFTTFB-UHFFFAOYSA-N 0.000 description 1
- UOPIILYKLVDKTK-UHFFFAOYSA-N 2-[1-(aminomethyl)-3-methylcyclohexyl]acetic acid Chemical compound CC1CCCC(CN)(CC(O)=O)C1 UOPIILYKLVDKTK-UHFFFAOYSA-N 0.000 description 1
- HYVKVSAZCPKHDV-UHFFFAOYSA-N 2-[1-(aminomethyl)-3-methylcyclopentyl]acetic acid Chemical compound CC1CCC(CN)(CC(O)=O)C1 HYVKVSAZCPKHDV-UHFFFAOYSA-N 0.000 description 1
- IRQCKMBXGOKUDW-UHFFFAOYSA-N 3-(1-azaniumylethyl)-5-methylhexanoate Chemical compound CC(C)CC(C(C)N)CC(O)=O IRQCKMBXGOKUDW-UHFFFAOYSA-N 0.000 description 1
- AYXYPKUFHZROOJ-UHFFFAOYSA-N 3-(azaniumylmethyl)-5-methylhexanoate Chemical compound CC(C)CC(CN)CC(O)=O AYXYPKUFHZROOJ-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000023697 ABri amyloidosis Diseases 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010018001 Gastrointestinal perforation Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 201000000162 ITM2B-related cerebral amyloid angiopathy 1 Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- 101500028027 Mus musculus Cathelin-related antimicrobial peptide Proteins 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 208000029650 alcohol withdrawal Diseases 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000573 anti-seizure effect Effects 0.000 description 1
- 230000010108 arterial embolization Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960003655 bromfenac Drugs 0.000 description 1
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 1
- HZFGMQJYAFHESD-UHFFFAOYSA-M bromfenac sodium Chemical compound [Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 HZFGMQJYAFHESD-UHFFFAOYSA-M 0.000 description 1
- 229960002716 bromfenac sodium Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000002567 electromyography Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000001761 ethyl methyl cellulose Substances 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 235000020888 liquid diet Nutrition 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 229910001120 nichrome Inorganic materials 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940039040 pregabalin 100 mg Drugs 0.000 description 1
- 229940039031 pregabalin 200 mg Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Addiction (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5675397P | 1997-08-20 | 1997-08-20 | |
| US60/056,753 | 1997-08-20 | ||
| US7479498P | 1998-02-16 | 1998-02-16 | |
| US60/074,794 | 1998-02-16 | ||
| US8293698P | 1998-04-24 | 1998-04-24 | |
| US60/082,936 | 1998-04-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020007001703A Division KR100609359B1 (ko) | 1997-08-20 | 1998-08-18 | 위장 손상의 예방 및 치료를 위한감마-아미노부티르산(ｇａｂａ) 동족체 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20050116168A true KR20050116168A (ko) | 2005-12-09 |
Family
ID=27369092
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020057022543A Ceased KR20050116168A (ko) | 1997-08-20 | 1998-08-18 | 위장 손상의 예방 및 치료를 위한감마-아미노부티르산(ｇａｂａ) 동족체 |
| KR1020007001703A Expired - Fee Related KR100609359B1 (ko) | 1997-08-20 | 1998-08-18 | 위장 손상의 예방 및 치료를 위한감마-아미노부티르산(ｇａｂａ) 동족체 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020007001703A Expired - Fee Related KR100609359B1 (ko) | 1997-08-20 | 1998-08-18 | 위장 손상의 예방 및 치료를 위한감마-아미노부티르산(ｇａｂａ) 동족체 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US6242488B1 (enExample) |
| EP (1) | EP1009399B1 (enExample) |
| JP (1) | JP4681116B2 (enExample) |
| KR (2) | KR20050116168A (enExample) |
| AT (1) | ATE461698T1 (enExample) |
| AU (2) | AU8668598A (enExample) |
| BR (1) | BR9812133A (enExample) |
| CA (1) | CA2297163C (enExample) |
| CO (1) | CO4960645A1 (enExample) |
| CY (1) | CY1109981T1 (enExample) |
| DE (1) | DE69841574D1 (enExample) |
| DK (1) | DK1009399T3 (enExample) |
| ES (1) | ES2341154T3 (enExample) |
| HU (1) | HUP0004551A3 (enExample) |
| IL (1) | IL134164A (enExample) |
| IS (1) | IS2749B (enExample) |
| MY (1) | MY155223A (enExample) |
| NO (1) | NO327983B1 (enExample) |
| NZ (1) | NZ502729A (enExample) |
| PE (1) | PE107299A1 (enExample) |
| PL (1) | PL194125B1 (enExample) |
| PT (1) | PT1009399E (enExample) |
| TW (2) | TW570794B (enExample) |
| UY (1) | UY25148A1 (enExample) |
| WO (2) | WO1999008670A1 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001876A (en) | 1996-07-24 | 1999-12-14 | Warner-Lambert Company | Isobutylgaba and its derivatives for the treatment of pain |
| WO1999012537A1 (en) | 1997-09-08 | 1999-03-18 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| EP1031350A1 (en) * | 1999-02-23 | 2000-08-30 | Warner-Lambert Company | Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain |
| CA2359485A1 (en) | 1999-03-10 | 2000-09-14 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| US6992109B1 (en) * | 1999-04-08 | 2006-01-31 | Segal Catherine A | Method for the treatment of incontinence |
| WO2000061188A1 (en) * | 1999-04-09 | 2000-10-19 | Euro-Celtique S.A. | Sodium channel blocker compositions and the use thereof |
| EP1840117A1 (en) * | 1999-06-10 | 2007-10-03 | Warner-Lambert Company LLC | Mono- and disubstituted 3-propyl gamma-aminobutyric acids |
| DE60034344T2 (de) | 1999-07-22 | 2008-01-10 | University Of Rochester | Methode zur behandlung der symptome hormoneller veränderungen, einschliesslich hitzewallungen |
| FR2801217B1 (fr) * | 1999-11-24 | 2002-12-06 | Aventis Pharma Sa | Association de riluzole et de gabapentine et son utilisation comme medicament |
| CA2408246A1 (en) | 2000-05-16 | 2001-11-22 | Warner-Lambert Company | Cell line for the expression of an .alpha.2.delta.2 calcium channel subunit |
| EP1343805A4 (en) | 2000-10-06 | 2005-07-20 | Xenoport Inc | COMPOUNDS DERIVED FROM GALLENIC ACIDS FOR THE PROVISION OF CONTINUING SYSTEMIC CONCENTRATIONS OF MEDICINAL PRODUCTS AFTER ORAL ADMINISTRATION |
| US6900192B2 (en) | 2000-10-06 | 2005-05-31 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
| EP1226820A1 (en) * | 2001-01-26 | 2002-07-31 | Warner-Lambert Company | Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| PT1404324E (pt) | 2001-06-11 | 2008-03-05 | Xenoport Inc | Formas de dosagem administradas oralmente de pró-fármacos análogas de gaba tendo toxicidade reduzida |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| AU2002345638A1 (en) | 2001-06-11 | 2002-12-23 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| US7232924B2 (en) | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| ATE317280T1 (de) | 2001-09-03 | 2006-02-15 | Newron Pharm Spa | Pharmazeutische zusammensetzung mit gabapentin oder deren analog und einem alpha-aminoamid und analgetische verwendung dieser zusammensetzung |
| US20060159743A1 (en) * | 2001-10-25 | 2006-07-20 | Depomed, Inc. | Methods of treating non-nociceptive pain states with gastric retentive gabapentin |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US7612112B2 (en) * | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| US20070184104A1 (en) * | 2001-10-25 | 2007-08-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
| AU2002316231A1 (en) | 2002-02-19 | 2003-09-29 | Xenoport, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| WO2003070237A1 (en) * | 2002-02-22 | 2003-08-28 | Warner-Lambert Company Llc | Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2 |
| US7026351B2 (en) | 2002-03-20 | 2006-04-11 | Xenoport, Inc. | Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof |
| WO2003099338A2 (en) | 2002-05-17 | 2003-12-04 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| JP2005533100A (ja) * | 2002-07-10 | 2005-11-04 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Ｇａｂａ誘導体を含む胃腸用組成物 |
| US7025745B2 (en) * | 2002-10-07 | 2006-04-11 | Advanced Cardiovascular Systems, Inc. | Method of making a catheter balloon using a tapered mandrel |
| US20040105881A1 (en) * | 2002-10-11 | 2004-06-03 | Gregor Cevc | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| US7060727B2 (en) | 2002-12-11 | 2006-06-13 | Xenoport, Inc. | Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof |
| NZ567457A (en) * | 2002-12-13 | 2009-08-28 | Warner Lambert Co | Alpha-2-delta ligand to treat lower urinary tract symptoms |
| KR100845932B1 (ko) * | 2002-12-13 | 2008-07-11 | 워너-램버트 캄파니 엘엘씨 | 섬유근육통 및 기타 관련 질환의 치료를 위한 프레가발린및 그의 유도체 |
| CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| WO2004078734A1 (en) | 2003-03-07 | 2004-09-16 | Warner-Lambert Company Llc | TETRAZOLE AND OXADIAZOLONE SUBSTITUTED β-AMINO ACID DERIVATIVES |
| WO2004084881A1 (en) * | 2003-03-21 | 2004-10-07 | Dynogen Pharmaceuticals, Inc. | METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS |
| US20050043407A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| EP1670451A4 (en) | 2003-09-11 | 2009-10-21 | Xenoport Inc | TREATMENT AND / OR PREVENTION OF URINARY INCONTINENCE AND PROMOTERS OF GABA ANALOGS |
| WO2005027850A2 (en) | 2003-09-17 | 2005-03-31 | Xenoport, Inc. | Treating or preventing restless legs syndrome using prodrugs of gaba analogs |
| KR101096480B1 (ko) | 2003-10-14 | 2011-12-20 | 제노포트 인코포레이티드 | 감마-아미노부티르산 유사체의 결정질 형태 |
| PL1691811T3 (pl) | 2003-12-11 | 2014-12-31 | Sunovion Pharmaceuticals Inc | Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji |
| RU2335342C2 (ru) * | 2004-03-12 | 2008-10-10 | Уорнер-Ламберт Компани Ллс | C1-симметричные бисфосфиновые лиганды и их применение в асимметрическом синтезе прегабалина |
| JP2007530657A (ja) * | 2004-04-01 | 2007-11-01 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | Ｐキラル性ホスホランの調製および不斉合成でのその使用 |
| EA200800909A1 (ru) | 2004-06-21 | 2008-08-29 | УОРНЕР-ЛАМБЕРТ КОМПАНИ ЭлЭлСи | Получение прегабалина и родственных соединений |
| SI1809271T1 (sl) * | 2004-09-10 | 2010-10-29 | Newron Pharm Spa | Uporaba (R)-(halobenziloksi) benzilamino propanamidov kot selektivnih modulatorjev natrijevih in/ali kalcijevih kanalov |
| US8795725B2 (en) | 2004-11-04 | 2014-08-05 | Xenoport, Inc. | GABA analog prodrug sustained release oral dosage forms |
| EP1963280B1 (en) | 2005-12-22 | 2015-10-28 | Newron Pharmaceuticals S.p.A. | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators |
| US20090176882A1 (en) * | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
| EA200970487A1 (ru) * | 2006-12-08 | 2009-12-30 | Ксенопорт, Инк. | Применение пролекарств аналогов гамк для лечения заболеваний |
| CA2703472A1 (en) * | 2007-10-26 | 2009-04-30 | The Scripps Research Institute | Methods for treating substance dependence |
| WO2009094577A2 (en) | 2008-01-25 | 2009-07-30 | Xenoport, Inc. | Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
| JP5563483B2 (ja) | 2008-01-25 | 2014-07-30 | ゼノポート，インコーポレイティド | アシロキシアルキルカルバメートプロドラッグの合成に使用されるアシロキシアルキルチオカーボネートの鏡像異性的な分解 |
| US7872046B2 (en) | 2008-01-25 | 2011-01-18 | Xenoport, Inc. | Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use |
| SG157299A1 (en) | 2008-05-09 | 2009-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| ES2589915T3 (es) | 2008-10-08 | 2016-11-17 | Xgene Pharmaceutical Inc | Conjugados de GABA y métodos de utilización de los mismos |
| CN104922084B (zh) * | 2009-06-22 | 2020-01-14 | 惠氏有限责任公司 | 布洛芬钠片剂和制备包含布洛芬钠的药物组合物的方法 |
| WO2011141923A2 (en) | 2010-05-14 | 2011-11-17 | Lupin Limited | Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin |
| WO2012059797A1 (en) | 2010-11-04 | 2012-05-10 | Lupin Limited | Process for synthesis of (s) - pregabalin |
| US9066853B2 (en) | 2013-01-15 | 2015-06-30 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable fiber |
| AU2014209028C1 (en) | 2013-01-28 | 2019-08-29 | Hector L. Lopez | Methods of improving tolerability, pharmacodynamics, and efficacy of b-alanine and use therefor |
| CN105997970A (zh) * | 2015-12-16 | 2016-10-12 | 南昌大学 | γ-氨基丁酸在制备胃粘膜保护剂中的应用 |
| US10874626B2 (en) | 2016-04-07 | 2020-12-29 | Nevakar Inc. | Formulation for use in a method of treatment of pain |
| WO2019070641A1 (en) | 2017-10-03 | 2019-04-11 | Nevakar Inc. | COMBINATIONS OF ACETAMINOPHENE-PRÉGABALINE AND METHODS OF TREATING PAIN |
| EP4227293A3 (en) | 2018-05-14 | 2023-10-04 | Xgene Pharmaceutical Inc | Crystalline forms of 1-(acyloxy)-alkyl carbamate drug conjugates of naproxen and pregabalin |
| CN116999560A (zh) * | 2022-04-30 | 2023-11-07 | 武汉思瓴生物科技有限公司 | 可治疗疼痛的药物组合及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE634102A (enExample) | ||||
| DE1963925C3 (de) | 1969-12-20 | 1975-07-10 | Desitin-Werk, Carl Klinke Gmbh, 2000 Hamburg | Verfahren zur Herstellung von N hoch 3-Carbalkoxyderivaten des 5,5-Diphenylhydantoins |
| JPS54110334A (en) | 1978-02-16 | 1979-08-29 | Fuji Chem Ind Co Ltd | Novel compounded anodyne and antiiinflammatory agent |
| US4158581A (en) | 1978-04-14 | 1979-06-19 | Westinghouse Electric Corp. | Method of making magnetic component for direct current apparatus |
| JPS61221121A (ja) | 1985-03-27 | 1986-10-01 | Nitto Electric Ind Co Ltd | テ−プ製剤 |
| US4694010A (en) | 1985-08-16 | 1987-09-15 | New York University | Anticonvulsant compositions and method |
| EP0346445A4 (en) | 1987-12-22 | 1990-03-28 | Ferkany John W | DEXTRORPHANE POTENTIALIZER FOR ANTISPASMODIC COMPOSITIONS AND METHODS. |
| AU9137091A (en) | 1990-11-27 | 1992-06-25 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
| GB9108362D0 (en) | 1991-04-18 | 1991-06-05 | Radoslavov Alexander | A pharmaceutical composition suitable for alleviation of headaches,migraine and other painful conditions |
| CZ286106B6 (cs) * | 1992-05-20 | 2000-01-12 | Northwestern University | Analogy GABA a L-glutamové kyseliny |
| US5234929A (en) | 1992-07-20 | 1993-08-10 | William Chelen | Method of treating motion sickness with anticonvulsants and antitussive agents |
| JPH06100468A (ja) | 1992-09-25 | 1994-04-12 | Kibun Food Chemifa Co Ltd | 徐放性組成物 |
| US5321012A (en) | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
| JPH06227969A (ja) | 1993-02-02 | 1994-08-16 | Masayasu Sugihara | 薬品の腸溶性改善方法およびそれにより得られた薬品組成物 |
| US5420270A (en) | 1993-10-07 | 1995-05-30 | G. D. Searle & Co. | Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use |
| US5352638A (en) | 1994-02-22 | 1994-10-04 | Corning Incorporated | Nickel aluminosilicate glass-ceramics |
| CA2197463A1 (en) | 1994-09-02 | 1996-03-14 | David J. Mayer | Composition alleviating pain, containing a non-narcotic analgesic and an analgesia enhancer |
| GB9420784D0 (en) * | 1994-10-14 | 1994-11-30 | Glaxo Group Ltd | Medicaments |
| CN1046199C (zh) | 1994-12-13 | 1999-11-10 | 凌吉安 | 复方消炎止痛霜剂 |
| DE69733081T2 (de) * | 1996-08-23 | 2006-05-11 | Endo Pharmaceuticals Inc. (n.d.Ges.d. Staates Delaware) | Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen |
| SE9603408D0 (sv) * | 1996-09-18 | 1996-09-18 | Astra Ab | Medical use |
| AU733896B2 (en) * | 1996-10-23 | 2001-05-31 | Warner-Lambert Company | Substituted gamma aminobutyric acids as pharmaceutical agents |
| US6127418A (en) * | 1997-08-20 | 2000-10-03 | Warner-Lambert Company | GABA analogs to prevent and treat gastrointestinal damage |
-
1998
- 1998-07-29 AU AU86685/98A patent/AU8668598A/en not_active Withdrawn
- 1998-07-29 WO PCT/US1998/015694 patent/WO1999008670A1/en not_active Ceased
- 1998-08-18 PL PL98338705A patent/PL194125B1/pl not_active IP Right Cessation
- 1998-08-18 TW TW087113592A patent/TW570794B/zh not_active IP Right Cessation
- 1998-08-18 DK DK98945758.5T patent/DK1009399T3/da active
- 1998-08-18 MY MYPI98003770A patent/MY155223A/en unknown
- 1998-08-18 AU AU92930/98A patent/AU9293098A/en not_active Abandoned
- 1998-08-18 HU HU0004551A patent/HUP0004551A3/hu unknown
- 1998-08-18 DE DE69841574T patent/DE69841574D1/de not_active Expired - Lifetime
- 1998-08-18 PT PT98945758T patent/PT1009399E/pt unknown
- 1998-08-18 TW TW092130045A patent/TWI251485B/zh not_active IP Right Cessation
- 1998-08-18 JP JP2000509411A patent/JP4681116B2/ja not_active Expired - Fee Related
- 1998-08-18 ES ES98945758T patent/ES2341154T3/es not_active Expired - Lifetime
- 1998-08-18 NZ NZ502729A patent/NZ502729A/xx not_active IP Right Cessation
- 1998-08-18 WO PCT/US1998/017082 patent/WO1999008671A1/en not_active Ceased
- 1998-08-18 CA CA002297163A patent/CA2297163C/en not_active Expired - Lifetime
- 1998-08-18 KR KR1020057022543A patent/KR20050116168A/ko not_active Ceased
- 1998-08-18 KR KR1020007001703A patent/KR100609359B1/ko not_active Expired - Fee Related
- 1998-08-18 IL IL13416498A patent/IL134164A/xx not_active IP Right Cessation
- 1998-08-18 BR BR9812133-2A patent/BR9812133A/pt not_active Application Discontinuation
- 1998-08-18 AT AT98945758T patent/ATE461698T1/de active
- 1998-08-18 EP EP98945758A patent/EP1009399B1/en not_active Expired - Lifetime
- 1998-08-19 CO CO98047372A patent/CO4960645A1/es unknown
- 1998-08-19 PE PE1998000745A patent/PE107299A1/es not_active Application Discontinuation
- 1998-08-20 UY UY25148A patent/UY25148A1/es unknown
-
2000
- 2000-01-25 IS IS5361A patent/IS2749B/is unknown
- 2000-02-17 NO NO20000786A patent/NO327983B1/no not_active IP Right Cessation
- 2000-05-09 US US09/567,191 patent/US6242488B1/en not_active Expired - Fee Related
-
2001
- 2001-03-13 US US09/804,742 patent/US6426368B2/en not_active Expired - Fee Related
-
2010
- 2010-04-26 CY CY20101100368T patent/CY1109981T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100609359B1 (ko) | 위장 손상의 예방 및 치료를 위한감마-아미노부티르산(ｇａｂａ) 동족체 | |
| US6127418A (en) | GABA analogs to prevent and treat gastrointestinal damage | |
| JP3018135B2 (ja) | 鎮痛剤 | |
| US6426338B1 (en) | Therapy for constipation | |
| Chojnacki et al. | Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis | |
| FR2559061A1 (fr) | Compositions analgesiques et anti-inflammatoires contenant de la diphenhydramine | |
| HUP0200344A2 (hu) | Gabapentinszármazék alkalmazása visceralis fájdalom megelőzésére és kezelésére | |
| Tomlinson et al. | Role of nonsteroidal anti-inflammatory drugs in gastrointestinal tract injury and repair | |
| Peng et al. | Gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs | |
| JP7328153B2 (ja) | 胆汁酸性下痢、小腸切除又は胆嚢除去及び短腸症候群に関連する下痢を治療するための方法及び組成物 | |
| EP0974351A2 (en) | Medicament for preventing and treating gastrointestinal damage | |
| HRP20020286A2 (en) | Synergistic combinations of an nk<sub>1</sub> receptor antagonist and a gaba structural analog | |
| AU2002317548B2 (en) | Gaba analogs to prevent and treat gastrointestinal damage | |
| Gerring | Effects of pharmacological agents on gastrointestinal motility | |
| Xu et al. | Mitigative effects of dehydrodiisoeugenol on enteritis and co-occurring dysmotility in murine model. | |
| Xue et al. | Afferent nerve sensitivity is decreased by an iNOS‐dependent mechanism during indomethacin‐induced inflammation in the murine jejunum in vitro | |
| MXPA00001093A (en) | Gaba analogs to prevent and treat gastrointestinal damage | |
| RU2684783C1 (ru) | Композиция антиоксидантов, пригодная для перорального применения в терапии воспалительного процесса в легких | |
| Mourad et al. | Role of 5-hydroxytryptamine in intestinal water and electrolyte movement during gut anaphylaxis. | |
| Blower | Non-steroidal anti-inflammatory drugs | |
| RU2527683C1 (ru) | Способ профилактики и лечения язвенной болезни желудка, вызываемой стрессом | |
| ES2425398T3 (es) | Antagonistas de receptor de colecistocinina-1 (CCK1) en el tratamiento de trastornos gastrointestinales y relacionados | |
| Tabrizi et al. | Effects of licofelone, a novel 5-LOX inhibitor, in comparison to celecoxib on gastric mucosa of dogs | |
| Clarke et al. | Highlights from the literature | |
| AU749784B2 (en) | Novel therapy for constipation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20051125 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20051221 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20060612 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20051221 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |